[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Atanackovic et al., 2016 - Google Patents

Chimeric Antigen Receptor (CAR) therapy for multiple myeloma

Atanackovic et al., 2016

Document ID
9307969002753003871
Author
Atanackovic D
Radhakrishnan S
Bhardwaj N
Luetkens T
Publication year
Publication venue
British journal of haematology

External Links

Snippet

The introduction of chimeric antigen receptor (CAR)‐modified T cells has revolutionized immunotherapy and cancer treatment as a whole. However, so far, clinical efficacy has only been demonstrated for CD 19‐positive B cell lymphomas. For Multiple Myeloma (MM), the …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes

Similar Documents

Publication Publication Date Title
Atanackovic et al. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma
Vago et al. Immune escape and immunotherapy of acute myeloid leukemia
Richards et al. CAR T cell therapy for neuroblastoma
Hodgins et al. Killers 2.0: NK cell therapies at the forefront of cancer control
Khair et al. Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma
Zhang et al. Targeting NK cell checkpoint receptors or molecules for cancer immunotherapy
Dagar et al. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Minetto et al. Harnessing NK cells for cancer treatment
Bachireddy et al. Haematological malignancies: at the forefront of immunotherapeutic innovation
Leone et al. Actors on the scene: immune cells in the myeloma niche
Yousefi et al. Immunotherapy of cancers comes of age
Haabeth et al. CD4+ T-cell–mediated rejection of MHC class II–positive tumor cells is dependent on antigen secretion and indirect presentation on host APCs
Mapara et al. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance
Lu et al. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
Beyar-Katz et al. Novel approaches to acute myeloid leukemia immunotherapy
Leblay et al. Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities
Sharma et al. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors
Brody et al. Active and passive immunotherapy for lymphoma: proving principles and improving results
Ansell et al. Immunotherapy of lymphomas
Murillo et al. In vivo depletion of DC impairs the anti‐tumor effect of agonistic anti‐CD137 mAb
Mucciolo et al. The dark side of immunotherapy: Pancreatic cancer
Varga et al. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma
Kolb Hematopoietic stem cell transplantation and cellular therapy
Marofi et al. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
Rotolo et al. The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma